Pilot study to evaluate the effect of short-term improvement in vitamin D status on glucose tolerance in patients with type 2 diabetes mellitus.
OBJECTIVE
To study the effect of improvement in vitamin D status on glucose tolerance in Asian Indian patients with moderately controlled type 2 diabetes mellitus (T2DM).


METHODS
This randomized, double-blind, placebo-controlled pilot study was conducted in 28 Asian Indian patients with T2DM. Study participants were randomly assigned to a vitamin D-treated group (group D) or a placebo group (group P). Serum 25-hydroxyvitamin D, hemoglobin A1c, and serum fructosamine levels were measured, and an oral glucose tolerance test (OGTT) was performed in all patients at baseline and 4 weeks after intervention. During the OGTT, plasma glucose and serum insulin levels were measured at 0, 30, 60, 90, and 120 minutes. The unpaired t test was used to compare the groups at baseline and to compare the differences in changes from baseline to 4 weeks between the 2 study groups.


RESULTS
Group D and group P were similar with respect to their fasting plasma glucose and serum insulin concentrations, post-OGTT plasma glucose and serum insulin levels, and hemoglobin A1c and fructosamine values at baseline. Serum 25-hydroxyvitamin D levels increased significantly in group D at 4 weeks. No significant differences were found between the groups at baseline and 4 weeks with respect to serum fructosamine, fasting plasma glucose and serum insulin, post-OGTT plasma glucose and serum insulin levels, and homeostasis model assessment of insulin resistance.


CONCLUSIONS
In this study, short-term improvement in vitamin D status was not associated with improvement in glucose tolerance, insulin secretion, or insulin sensitivity in Asian Indian patients with moderately controlled T2DM.
Parekh
Deepal
D
Department of Endocrinology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Sarathi
Vijaya
V
Shivane
Vyankatesh K
VK
Bandgar
Tushar R
TR
Menon
Padma S
PS
Shah
Nalini S
NS
D015652:25-Hydroxyvitamin D 2 / Q000097:blood; D000328:Adult; D044466:Asian People; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002112:Calcifediol / Q000097:blood; D002762:Cholecalciferol / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000503:physiopathology*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D019270:Fructosamine / Q000097:blood; D018149:Glucose Intolerance / Q000503:physiopathology*; D006442:Glycated Hemoglobin / Q000032:analysis; D006706:Homeostasis; D006801:Humans; D007194:India; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D014808:Vitamin D Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy*
D015652:25-Hydroxyvitamin D 2; D001786:Blood Glucose; D002112:Calcifediol; D002762:Cholecalciferol; D019270:Fructosamine; D006442:Glycated Hemoglobin; D007328:Insulin; C517652:hemoglobin A1c protein, human